Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
出版年份 2023 全文链接
标题
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
作者
关键词
-
出版物
LANCET
Volume 402, Issue 10403, Pages 705-719
出版商
Elsevier BV
发表日期
2023-06-26
DOI
10.1016/s0140-6736(23)01185-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal
- (2023) Connor Enright et al. Journal of the Endocrine Society
- Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
- (2023) Marlene Chakhtoura et al. EClinicalMedicine
- Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
- (2023) Vanita R Aroda et al. LANCET
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
- (2022) John P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Adverse drug reactions of GLP-1 agonists: A systematic review of case reports
- (2022) Rashmi Shetty et al. Diabetes & Metabolic Syndrome-Clinical Research & Reviews
- Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
- (2022) Mikhail N. Kosiborod et al. DIABETES OBESITY & METABOLISM
- Semaglutide for the treatment of overweight and obesity: A review
- (2022) Natasha Chidekel Bergmann et al. DIABETES OBESITY & METABOLISM
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
- (2022) W. Timothy Garvey et al. NATURE MEDICINE
- 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023
- (2022) Nuha A. ElSayed et al. DIABETES CARE
- Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials
- (2022) Subodh Verma et al. EClinicalMedicine
- Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data
- (2021) Sean Wharton et al. INTERNATIONAL JOURNAL OF OBESITY
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
- (2021) Sean Wharton et al. DIABETES OBESITY & METABOLISM
- Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
- (2021) Baptist Gallwitz et al. Frontiers in Endocrinology
- Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
- (2021) Ildiko Lingvay et al. LANCET
- Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
- (2020) Mansoor Husain et al. Cardiovascular Diabetology
- Pharmacotherapy for Obesity—Trends Using a Population Level National Database
- (2020) Abbinaya Elangovan et al. OBESITY SURGERY
- Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
- (2020) Kristina Boye et al. DIABETES OBESITY & METABOLISM
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
- (2020) Martin Friedrichsen et al. DIABETES OBESITY & METABOLISM
- Factors affecting weight loss variability in obesity
- (2020) Robert Dent et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Obesity: global epidemiology and pathogenesis
- (2019) Matthias Blüher Nature Reviews Endocrinology
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation
- (2017) G.A. Bray et al. Obesity Reviews
- From C-Reactive Protein to Interleukin-6 to Interleukin-1
- (2016) Paul M Ridker CIRCULATION RESEARCH
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events
- (2016) Rohan Khera et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Missing data in clinical trials for weight management
- (2015) Bradley W. McEvoy Journal of Biopharmaceutical Statistics
- European Guidelines for Obesity Management in Adults
- (2015) Volkan Yumuk et al. Obesity Facts
- Biological mechanisms that promote weight regain following weight loss in obese humans
- (2013) Christopher N. Ochner et al. PHYSIOLOGY & BEHAVIOR
- Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management
- (2010) Steven R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started